2014 Volume 15 Issue 2 Pages 96-101
Although pharmacists participate in vancomycin (VCM) administration planning in hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) pneumonia, their contribution has not been assessed in terms of health economics. Here we report comparative cost-effectiveness study on VCM administration planning in HA-MRSA pneumonia based on medical records. We separated the patients into two groups；pharmacist participation group (15 patients) and control group (15 patients). In the pharmacist participation group, incidences of nephrotoxicity and expected cost were 0% and 419,088.0 yen, respectively, while in the control group, the results were 13.3% and 485,610.5 yen, respectively. Thus, we demonstrate that the pharmacist participation group is a more beneficial strategy, as it is safer and has lower cost compared to the control group. Hence, VCM administration planning by pharmacist in HA-MRSA pneumonia is recommended in terms of medical economics, for its better safety and shorter treatment duration.
